StockpollyBeta
Get App
Popularity #1,125
INCY · NASDAQ · Biotechnology

Incyte (INCY)

Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.

$126.31
vs last close+1.66 (+1.33%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue9191,0138811,0441,1381,1791,0531,2161,3661,5071,2731,674
Cost of revenue607061778689737999121105105
Gross profit8599448209671,0521,0909801,1371,2671,3861,1681,569
6447567281,4459067937638268361,002844871
Research & development3764444291,138573466437495507611516517
268294300286309327326331329390328352
General & administrative2682943002863093273263313293903280
Other expenses118−221230000002
Operating income21518792−478146297217311431384324698
1984144881016172475161954
Interest income0000021232527313438
Interest expense110110111111
Other non-operating income−20−84−145−89−11−17−18−248−52−7−20−54
Income before tax234271236−390157314234558482390344752
Income tax expense637067555011376153589140166
Net income from continuing operations171201170−445106201158405424299303586
Net income171201170−445106201158405424299303586
EPS, basic$0.76$0.90$0.76−$2.04$0.55$1.04$0.82$2.09$2.17$1.52$1.52$2.92
EPS, diluted$0.76$0.89$0.75−$2.04$0.54$1.02$0.80$2.04$2.11$1.46$1.47$2.81
Weighted average shares, basic224224224218193193194194196197199200
Weighted average shares, diluted226226227218196197198199201205207208
EBITDA256294259−367180337257582507415368752
Depreciation & amortization21222222232322232424240
EBIT234272237−389157314235559483391344752